Global Dry Eye Drugs Revenue Is Nearly 37 Billion USD In 2017
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
In the last several years, global market of Dry Eye Drugs developed rapidly, with an average growth rate of 11.84% during 2013 to 2017. In 2017, global revenue of Dry Eye Drugs is nearly 37 Billion USD; the actual sales are about 390 Million Unit.
The global average price of Dry Eye Drugs is in the increasing trend, from 8.48 USD/Unit in 2013 to 9.49 USD/Unit in 2017. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Dry Eye Drugs includes Artificial?Tears, Anti-inflammatory?drugs and other, and the proportion of Artificial?Tears in 2017 is about 89%.
Dry Eye Drugs is widely used in Hospital, Drug?Stores and Online?Pharmacies?. The most proportion of Dry Eye Drugs is used in hospitals, and proportion is about 42%.
North America is the largest consumption place, with a consumption market share nearly 40% in 2017. Following North America, Asia Pacific is the second largest consumption place with the consumption market share of 25%.
Market competition is intense. Allergan, Novartis AG, Valeant Pharmaceuticals, Santen Pharma, Shire, Johnson & Johnson, United Laboratories, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.